The investment bank provided the updates as part of its 2017 outlook on the US life science tools and diagnostics markets.
The investment bank noted Veracyte's "disciplined" approach to developing and commercializing tests, and said the company stands out in its sector.
The GenomeWeb Index gained more than 5 percent in September, after falling more than 2 percent in August, and outperformed the Nasdaq Biotechnology Index.
The investment bank said it has heard positive feedback from early adopters in Europe of GenMark's ePlex system and respiratory panel.
New products and a more normal 2016-17 flu season could accelerate revenues for Quidel, the investment bank said.
The investment bank said the company's stock has "swung to the upside" following a reimbursement decision from the Centers for Medicare and Medicaid Services.
The investment bank also raised its outlook on the life science tools sector, lowered its view of labs, and stayed steady on diagnostics.
The investment firm said the potential for T2's upcoming bacteria sepsis panel outweighs concerns over a lackluster launch for its Candida panel.
The cancer diagnostics firm could be poised for a return to growth following a transition that has seen its share price drop 16 percent in the year to date.
The investment bank noted stabilization in Myriad's BRCA1/2 testing franchise, the firm's new management, and its new products.
In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.
Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.
Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.
In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.